146 related articles for article (PubMed ID: 15373115)
1. [AT 1-blocker can be given in addition to ACE inhibitor and beta blocker. "Triple therapy decidedly well tolerated even in severe heart failure"].
Dietz R
MMW Fortschr Med; 2004 May; 146(22):50. PubMed ID: 15373115
[No Abstract] [Full Text] [Related]
2. [Pharmocological therapeutics for chronic heart failure--how to use ARB (angiotensin receptor blocker].
Kudo Y; Komuro I; Akazawa H
Nihon Rinsho; 2007 May; 65 Suppl 5():84-9. PubMed ID: 17571370
[No Abstract] [Full Text] [Related]
3. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
4. [Therapy of heart failure. Which patients does the AT1 blocker help?].
Böhm M
MMW Fortschr Med; 2003 Sep; 145(38):8. PubMed ID: 14603671
[No Abstract] [Full Text] [Related]
5. [AT1 blockers against heart failure. The charm of polypharmacy].
MMW Fortschr Med; 2003 Sep; 145(38):6. PubMed ID: 14603670
[No Abstract] [Full Text] [Related]
6. [Therapy of heart failure. 2 neurohormone blockers are enough].
MMW Fortschr Med; 2002 Sep; 144(35-36):57. PubMed ID: 12380364
[No Abstract] [Full Text] [Related]
7. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.
McMurray JJ; Pitt B; Latini R; Maggioni AP; Solomon SD; Keefe DL; Ford J; Verma A; Lewsey J;
Circ Heart Fail; 2008 May; 1(1):17-24. PubMed ID: 19808266
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of candesartan, enalapril and their combination in congestive heart failure].
Rapezzi C
Ital Heart J Suppl; 2000 Mar; 1(3):429-30. PubMed ID: 10815278
[No Abstract] [Full Text] [Related]
9. [CHARM study--new strategy for the treatment of heart failure].
Hasegawa H; Komuro I
Nihon Rinsho; 2004 May; 62(5):995-1002. PubMed ID: 15148833
[TBL] [Abstract][Full Text] [Related]
10. Initial data supporting the design of the Candesartan in Heart failure--assessment of reduction in mortality and morbidity (CHARM) programme.
McKelvie RS
J Hypertens Suppl; 2006 Mar; 24(1):S9-13. PubMed ID: 16601580
[TBL] [Abstract][Full Text] [Related]
11. [Use of angiotensin II receptor blockaders in heart failure].
Bonarjee VV; Dickstein K
Tidsskr Nor Laegeforen; 2000 Mar; 120(7):817-21. PubMed ID: 10806906
[TBL] [Abstract][Full Text] [Related]
12. [Improved protection of heart and kidneys in the hypertensive patient. ACE inhibitor and AT1 blocker combined?].
MMW Fortschr Med; 2003 Jun; 145(23):59. PubMed ID: 12854231
[No Abstract] [Full Text] [Related]
13. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
McMurray JJ; Young JB; Dunlap ME; Granger CB; Hainer J; Michelson EL; Earle S; Olofsson B; Ostergren J; Yusuf S; Swedberg K; Pfeffer MA;
Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319
[TBL] [Abstract][Full Text] [Related]
14. Lack of deleterious interaction between angiotensin receptor blockers and beta-blockers in the treatment of patients with heart failure.
Hennekens CH; Kowalczykowski M; Hollar D
J Cardiovasc Pharmacol Ther; 2006 Jun; 11(2):149-52. PubMed ID: 16891293
[TBL] [Abstract][Full Text] [Related]
15. [When after myocardial infarction a pump weakness remains. ACE inhibitors and AT-1 blockers equivalent].
MMW Fortschr Med; 2003 Dec; 145(49):18-9. PubMed ID: 14963986
[No Abstract] [Full Text] [Related]
16. [ACE inhibitors or AT1 receptor antagonists?].
Riegger GA
Dtsch Med Wochenschr; 1999 Sep; 124 Suppl 2():S37-9. PubMed ID: 10535045
[No Abstract] [Full Text] [Related]
17. Angiotensin II type 1 receptor blockade: high hopes sent back to reality?
Grothusen A; Divchev D; Luchtefeld M; Schieffer B
Minerva Cardioangiol; 2009 Dec; 57(6):773-85. PubMed ID: 19942847
[TBL] [Abstract][Full Text] [Related]
18. [Conclusions from CHARM interview with Prof. Veselin Mitrovich, Bad Nauheim. Strong evidence: more help for weak hearts].
Mitrovic V
MMW Fortschr Med; 2005 Mar; 147(13):48-9. PubMed ID: 15832762
[No Abstract] [Full Text] [Related]
19. Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
Weir RA; McMurray JJ; Puu M; Solomon SD; Olofsson B; Granger CB; Yusuf S; Michelson EL; Swedberg K; Pfeffer MA;
Eur J Heart Fail; 2008 Feb; 10(2):157-63. PubMed ID: 18242128
[TBL] [Abstract][Full Text] [Related]
20. [Clinical trials of ACE inhibitors and ARB for treatment of patients with hypertension, heart failure, and diabetic nephropathy in Japan--special reference to the dosage schedule and adverse effects].
Kageyama S
Nihon Yakurigaku Zasshi; 2008 Mar; 131(3):180-1. PubMed ID: 18421844
[No Abstract] [Full Text] [Related]
[Next] [New Search]
